Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists.

[1]  M. Piccart,et al.  Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis , 2013, Advances in Therapy.

[2]  S. Sonis,et al.  Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. , 2013, Oral surgery, oral medicine, oral pathology and oral radiology.

[3]  R. Chlebowski.  Changing concepts of hormone receptor-positive advanced breast cancer therapy. , 2013, Clinical breast cancer.

[4]  G. Hortobagyi,et al.  Clinical management and resolution of stomatitis in BOLERO-2. , 2013 .

[5]  G. Hortobagyi,et al.  Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. , 2013 .

[6]  P. Neven,et al.  Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial , 2013, Cancer.

[7]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[8]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[9]  R. Motzer,et al.  Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors , 2012, Cancer.

[10]  J. Dancey,et al.  Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Kasiske,et al.  A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation , 2012, Journal of transplantation.

[12]  I. Ray-Coquard,et al.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Davila,et al.  Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer , 2012, Nature Reviews Clinical Oncology.

[14]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[15]  J. Machiels,et al.  An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. , 2012, European journal of cancer.

[16]  A. Larionov,et al.  Edinburgh Research Explorer Understanding the mechanisms of aromatase inhibitor resistance , 2022 .

[17]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[18]  Jeffrey W. Clark,et al.  Phase 1/2 study of everolimus in advanced hepatocellular carcinoma , 2011, Cancer.

[19]  A. Paci,et al.  Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. , 2011, European journal of cancer.

[20]  G. Demetri,et al.  Clinical presentation and management of mTOR inhibitor-associated stomatitis. , 2011, Oral oncology.

[21]  N. Treister,et al.  Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors. , 2011, Clinical journal of oncology nursing.

[22]  S. Fox,et al.  “Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future? , 2011, Breast Cancer Research and Treatment.

[23]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[24]  C. Porta,et al.  Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. , 2011, European journal of cancer.

[25]  A. Brenner,et al.  Common toxicities of mammalian target of rapamycin inhibitors , 2011, Targeted Oncology.

[26]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[27]  Hyun-Ah Kim,et al.  Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer , 2011, Breast Cancer Research and Treatment.

[28]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[29]  Funda Meric-Bernstam,et al.  Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. , 2010, Clinical breast cancer.

[30]  A. Ravaud,et al.  Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. , 2010, American journal of respiratory and critical care medicine.

[31]  D. Rea,et al.  Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer , 2010, Breast Cancer Research and Treatment.

[32]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  S. Johnston,et al.  New Strategies in Estrogen Receptor–Positive Breast Cancer , 2010, Clinical Cancer Research.

[34]  J. D. de Fijter,et al.  mTOR inhibitor‐associated dermatologic and mucosal problems , 2010, Clinical transplantation.

[35]  A. Kibel.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2009 .

[36]  L. Schwartz,et al.  Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001) , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  G. Demetri,et al.  Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients , 2009, Cancer.

[38]  Robert Dufour,et al.  Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .

[39]  M. Ellis,et al.  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Eric Sauerbrei,et al.  Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Pascual.  The use of everolimus in renal-transplant patients , 2009, International journal of nephrology and renovascular disease.

[42]  R. Greil,et al.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Pike,et al.  American Journal of Epidemiology Original Contribution Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status the Multiethnic Cohort Study , 2022 .

[44]  Funda Meric-Bernstam,et al.  Targeting the mTOR signaling network for cancer therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  F. Giles,et al.  The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents , 2009, Targeted Oncology.

[46]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[47]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[48]  Flora T. Musuamba,et al.  Pharmacokinetics and dosage adjustment in patients with renal dysfunction , 2008, European Journal of Clinical Pharmacology.

[49]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[50]  A. Berkenblit,et al.  Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  S. Johnston,et al.  Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. , 2006, Breast.

[52]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[53]  Manuel Hidalgo,et al.  Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.

[54]  Y. Samuels,et al.  Oncogenic mutations of PIK3CA in human cancers. , 2004, Current topics in microbiology and immunology.

[55]  Anthony Howell,et al.  Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  M. Bjornsti,et al.  The tor pathway: a target for cancer therapy , 2004, Nature Reviews Cancer.

[57]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[58]  Nilanjan Chatterjee,et al.  Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database , 2002, Breast Cancer Research and Treatment.

[59]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[60]  U. Christians,et al.  Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. , 2001, Transplantation proceedings.

[61]  J. Squifflet,et al.  Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. , 2000, Transplantation.